Showing 109 to 120 of 152 results
New Obesity Drugs Achieve Significant Weight Loss, Challenging Traditional Approaches
New drugs, such as semaglutide and tirzepatide, are revolutionizing obesity treatment by mimicking key hormones that regulate appetite and metabolism, achieving significant weight loss (up to 25%) in clinical trials, while traditional methods often fail in the long term; this has led to a surge in p...
New Obesity Drugs Achieve Significant Weight Loss, Challenging Traditional Approaches
New drugs, such as semaglutide and tirzepatide, are revolutionizing obesity treatment by mimicking key hormones that regulate appetite and metabolism, achieving significant weight loss (up to 25%) in clinical trials, while traditional methods often fail in the long term; this has led to a surge in p...
Progress
48% Bias Score
Moderna Stock Surges on Patent Win, but Weak Financials Raise Concerns
Moderna's stock jumped 16% after winning a patent infringement case against BioNTech and Pfizer, but its weak recent financial performance, including a 66% quarterly revenue drop and negative operating margins, raises concerns for investors despite a strong balance sheet.
Moderna Stock Surges on Patent Win, but Weak Financials Raise Concerns
Moderna's stock jumped 16% after winning a patent infringement case against BioNTech and Pfizer, but its weak recent financial performance, including a 66% quarterly revenue drop and negative operating margins, raises concerns for investors despite a strong balance sheet.
Progress
60% Bias Score
Pharmaceutical Firms Oppose EU's Rushed Medicine Shortage Act
The European Commission's proposed Critical Medicines Act, aiming to prevent medicine shortages in the EU by March 11th, faces opposition from major pharmaceutical companies like Roche and Bayer due to concerns over insufficient impact assessment and rushed preparation, prompting calls for a more th...
Pharmaceutical Firms Oppose EU's Rushed Medicine Shortage Act
The European Commission's proposed Critical Medicines Act, aiming to prevent medicine shortages in the EU by March 11th, faces opposition from major pharmaceutical companies like Roche and Bayer due to concerns over insufficient impact assessment and rushed preparation, prompting calls for a more th...
Progress
48% Bias Score
€343 Million Spent on EU Lobbying in 2024: Analysis Reveals Industry Influence
A new analysis reveals that 162 major corporations and trade associations spent €343 million on lobbying EU lawmakers and officials in 2024, a 13% increase from the previous year and a significant rise since 2020, highlighting concerns about industry influence on EU policy.
€343 Million Spent on EU Lobbying in 2024: Analysis Reveals Industry Influence
A new analysis reveals that 162 major corporations and trade associations spent €343 million on lobbying EU lawmakers and officials in 2024, a 13% increase from the previous year and a significant rise since 2020, highlighting concerns about industry influence on EU policy.
Progress
44% Bias Score
First Spanish Child Cured of Wiskott-Aldrich Syndrome via Gene Therapy
Five-year-old Javier, diagnosed with Wiskott-Aldrich syndrome at six months old, is the first child in Spain cured using gene therapy; this case highlights the potential of gene therapy and challenges of accessing innovative treatments for rare diseases affecting less than 1 in 250,000 male births.
First Spanish Child Cured of Wiskott-Aldrich Syndrome via Gene Therapy
Five-year-old Javier, diagnosed with Wiskott-Aldrich syndrome at six months old, is the first child in Spain cured using gene therapy; this case highlights the potential of gene therapy and challenges of accessing innovative treatments for rare diseases affecting less than 1 in 250,000 male births.
Progress
40% Bias Score
CSL Profits Rise Despite Flu Vaccine Revenue Drop Amid US Vaccine Hesitancy
CSL reported a 7 percent increase in net profit to $US2.01 billion, but its flu vaccine unit, Seqirus, experienced a 9 percent revenue drop due to lower US vaccination rates in the 18-64 age group, amid rising vaccine skepticism and Robert F Kennedy Jr.'s potential appointment as US Health Secretary...
CSL Profits Rise Despite Flu Vaccine Revenue Drop Amid US Vaccine Hesitancy
CSL reported a 7 percent increase in net profit to $US2.01 billion, but its flu vaccine unit, Seqirus, experienced a 9 percent revenue drop due to lower US vaccination rates in the 18-64 age group, amid rising vaccine skepticism and Robert F Kennedy Jr.'s potential appointment as US Health Secretary...
Progress
40% Bias Score
Trump's Pharmaceutical Tariffs: A Risky Gamble
President Trump's proposed reciprocal tariffs on pharmaceuticals, potentially effective April 2, aim to boost domestic manufacturing but risk higher drug prices and shortages in the U.S. due to increased costs and skepticism from major overseas manufacturers.
Trump's Pharmaceutical Tariffs: A Risky Gamble
President Trump's proposed reciprocal tariffs on pharmaceuticals, potentially effective April 2, aim to boost domestic manufacturing but risk higher drug prices and shortages in the U.S. due to increased costs and skepticism from major overseas manufacturers.
Progress
52% Bias Score
Eli Lilly's $27 Billion Investment: High-Risk, High-Reward Strategy
Eli Lilly will invest $27 billion in four new US manufacturing plants over five years, creating thousands of jobs, a strategic move amid potential import tariffs; despite its high valuation (P/E 120.8, P/S 17.8 vs S&P 500's 24.4 and 3.1), the company shows strong revenue growth (27.4% last 12 months...
Eli Lilly's $27 Billion Investment: High-Risk, High-Reward Strategy
Eli Lilly will invest $27 billion in four new US manufacturing plants over five years, creating thousands of jobs, a strategic move amid potential import tariffs; despite its high valuation (P/E 120.8, P/S 17.8 vs S&P 500's 24.4 and 3.1), the company shows strong revenue growth (27.4% last 12 months...
Progress
52% Bias Score
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Progress
48% Bias Score
Teva's Market Cap Falls $6 Billion Despite Positive 2024 Results
Teva Pharmaceutical Industries' market cap fell by roughly $6 billion to $18.8 billion after its 2025 profit guidance disappointed investors despite positive 2024 results that exceeded expectations, prompting CEO Richard Francis to highlight the company's growth strategy focusing on branded drugs.
Teva's Market Cap Falls $6 Billion Despite Positive 2024 Results
Teva Pharmaceutical Industries' market cap fell by roughly $6 billion to $18.8 billion after its 2025 profit guidance disappointed investors despite positive 2024 results that exceeded expectations, prompting CEO Richard Francis to highlight the company's growth strategy focusing on branded drugs.
Progress
52% Bias Score
Australian Pharmacy Merger Creates Billionaire Trio
The merger of Chemist Warehouse and Sigma Healthcare in Australia created a pharmacy giant, making over 100 shareholders millionaires, including three billionaires, and increasing the stock price by 5.4% on the first day of trading.
Australian Pharmacy Merger Creates Billionaire Trio
The merger of Chemist Warehouse and Sigma Healthcare in Australia created a pharmacy giant, making over 100 shareholders millionaires, including three billionaires, and increasing the stock price by 5.4% on the first day of trading.
Progress
52% Bias Score
GSK CEO urges UK government to boost support for pharma industry
GSK's CEO Emma Walmsley says the UK government must increase support for its pharmaceutical industry to prevent it being overtaken by foreign rivals, following AstraZeneca's cancellation of a £450 million vaccine factory near Liverpool due to insufficient state support.
GSK CEO urges UK government to boost support for pharma industry
GSK's CEO Emma Walmsley says the UK government must increase support for its pharmaceutical industry to prevent it being overtaken by foreign rivals, following AstraZeneca's cancellation of a £450 million vaccine factory near Liverpool due to insufficient state support.
Progress
44% Bias Score
Showing 109 to 120 of 152 results